KRAS and colorectal carcinoma: Our findings suggest that screening of ctDNA and miRNA will be a predictor for decision making in the early identification of patients, regarding who will have primary tumor DNA, and accordingly, who may benefit from adjuvant chemotherapies, such as cetuximab or bevacizumab for KRAS-mutated CRC patients.